Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
RecruitingOBSERVATIONAL
Enrollment
65
Participants
Timeline
Start Date
November 25, 2022
Primary Completion Date
June 1, 2025
Study Completion Date
June 1, 2025
Conditions
NSCLC
Trial Locations (1)
100142
RECRUITING
Yuyan Wang, Beijing
All Listed Sponsors
collaborator
Geneplus-Beijing Co. Ltd.
INDUSTRY
lead
Peking University Cancer Hospital & Institute
OTHER
NCT06081777 - Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter